Clinical Takeaway
People with PTSD and co-occurring substance use disorders who use cannabis can still benefit meaningfully from trauma-focused treatments, and cannabis use does not appear to undermine treatment outcomes compared to non-users. Clinicians should not withhold or delay evidence-based trauma-focused care for patients simply because they report cannabis use alongside other substance use disorders.
#6 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis clarifies whether trauma-focused treatments maintain efficacy in the substantial subset of PTSD+SUD patients who use cannabis concurrently, addressing a critical clinical gap since cannabis use is highly prevalent in this population yet rarely studied as a moderator in treatment trials. The findings directly inform treatment selection and outcome expectations for clinicians managing the increasingly common presentation of comorbid PTSD, cannabis use, and other substance use disorders. Understanding whether cannabis use compromises evidence-based PTSD treatment response has significant implications for individualizing intervention strategies and counseling patients about realistic treatment outcomes in this complex patient population.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 This meta-analysis examining trauma-focused treatment outcomes in patients with co-occurring PTSD and substance use disorders who also use cannabis addresses a clinically relevant gap, though several limitations warrant cautious interpretation. The analysis draws from a subset of four RCTs within a larger Project Harmony dataset, which constrains generalizability and statistical power compared to the full cohort, and the heterogeneity of cannabis use patterns (frequency, potency, concurrent with other substances) across participants remains largely uncharacterized. Cannabis may function variously as self-medication for PTSD symptoms, a confounding variable affecting treatment engagement, or a contributor to poor outcomes through cognitive or motivational effects, but this meta-analysis design cannot definitively distinguish these mechanisms. Importantly, the long-term trajectory of patients who continue cannabis use during evidence-based PTSD treatment remains incompletely understood, and individual variations in cannabis metabolism and cannabinoid sensitivity mean population-level findings may not predict individual responses. In clinical practice, these findings suggest that concurrent